Hepatic Impairment

Oncology·MeSH: Fibrosis

13 drugs in development·11 companies·16 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
AZD2693	ASTRAZENECA PLC (AZN)
Capivasertib	ASTRAZENECA PLC (AZN)
fazirsiran	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
fazirsiran	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
pelabresib	Novartis AG (NVS)
pelabresib	Novartis AG (NVS)
Treprostinil Palmitil	INSMED Inc (INSM)

Phase 2(1)

Drug	Company
nnc0194-0499	Novo Nordisk A/S (NVO)

Phase 1(4)

Drug	Company
amg 133	AMGEN INC (AMGN)
dazucorilant	CORCEPT THERAPEUTICS INC (CORT)
nalbuphine er	Trevi Therapeutics, Inc. (TRVI)
tazemetostat	Epizyme, Inc. (EPZM)

Phase 1/Phase 2(1)

Drug	Company
Nemtabrutinib	Merck & Co., Inc. (MRK)

BioSniper tracks 13 drugs in development for Hepatic Impairment across 11 companies.

There are 16 clinical trials targeting Hepatic Impairment tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.